Details
As disease-modifying therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) continue to advance, accurately tracking disease progression is essential.
This review explores the key markers clinicians can use to monitor progression—including NT-proBNP, eGFR, 6-minute walk distance, diuretic use, symptom burden, and cardiac imaging metrics.